Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Universal Vision Biotechnology (3218 TT): Not Suffering from Myopia; Clear Long-Term Growth Prospect

Universal Vision Biotechnology (3218 TT): Steady Revenue and Net Profit Growth in 2022;

Universal Vision Biotechnology (3218 TT): Steady Growth Continued in 1H23 Riding on Strong Demand

Equity Bottom-Up

Universal Vision Biotechnology / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/universal-vision-biotechnology-co-ltd" target="_blank" data-smartkarma-citation="entities:8112:1" rel="noopener">Universal Vision Biotechnology (3218 TT)</a> is struggling with expansion plans, decelerated revenue growth, and unfavorable revenue mix. 2024 revenue growth of 4% is significant deterioration from 17% reported in 2023.</li>
<li>China business remained challenging. In 2024, revenue from China 22% YoY to NT$594M.  Both the number of partnered hospitals and self-operated clinics/hospitals in China decreased during 2024.</li>
<li>Through the first three months of 2025, revenue growth has not shown any sign of improvement. 1Q25 revenue grew just 5% YoY to NT$1,123M.</li>
</ul>



Universal Vision Biotechnology (3218 TT) is struggling with expansion plans, decelerated revenue growth, and unfavorable revenue mix. 2024 revenue growth of 4% is significant deterioration from 17% reported in 2023.
China business remained challenging. In 2024, revenue from China 22% YoY to NT$594M.  Both the number of partnered hospitals and self-operated clinics/hospitals in China decreased during 2024.
Through the first three months of 2025, revenue growth has not shown any sign of improvement. 1Q25 revenue grew just 5% YoY to NT$1,123M.


Universal Vision Biotechnology (3218 TT): There Are Plenty of Near-Term Pain Points